van Leeuwen-Stok A E, Schuurhuis G J, Dräger A M, Visser-Platier A W, Teule G J, Huijgens P C
Department of Hematology, Free University Hospital, Amsterdam, The Netherlands.
Br J Cancer. 1996 Aug;74(4):619-24. doi: 10.1038/bjc.1996.411.
Gallium-67 is a radionuclide that accumulates in haematological malignancies and is used for diagnostic purposes. Uptake of 67Ga into the cell occurs via the transferrin receptor, which is differentially expressed during the various cell cycle phases. With the aim of selectively increasing 67Ga uptake, we studied whether the transferrin receptor (TfR) expression could be modulated in the U937 and U715 lymphoma cell lines by cytostatic drugs inducing cell cycle phase accumulation. We tested clinically relevant drugs such as 1-beta-D-arabinofuranosylcytosine (Ara-C), hydroxyurea and methotrexate. Cytotoxicity was determined by testing the clonogenic capacity of the lymphoma cell lines. All three drugs induced an increase in S-phase content, TfR expression and 67Ga uptake in U937 and U715 single cells. The combinations of drugs and 67Ga resulted in an additive effect on the clonogenic capacity. In U937 spheroids, cultured by the fibrin clot technique, we found an accumulation in the S-phase too as well as an increase of the transferrin receptor expression after Ara-C preincubation. As in single cells 67Ga uptake was increased without synergistic effects on the clonogenic capacity. In conclusion, priming with drugs induces increased transferrin receptor expression and 67Ga uptake. Inhibition of clonogenic capacity was additive rather than synergistic.
镓-67是一种放射性核素,可在血液系统恶性肿瘤中蓄积并用于诊断目的。67Ga通过转铁蛋白受体进入细胞,该受体在细胞周期的不同阶段差异表达。为了选择性地增加67Ga的摄取,我们研究了细胞周期停滞药物诱导细胞周期阶段积累是否能调节U937和U715淋巴瘤细胞系中转铁蛋白受体(TfR)的表达。我们测试了临床上常用的药物,如1-β-D-阿拉伯呋喃糖基胞嘧啶(Ara-C)、羟基脲和甲氨蝶呤。通过检测淋巴瘤细胞系的克隆形成能力来确定细胞毒性。所有三种药物均能使U937和U715单细胞的S期含量、TfR表达和67Ga摄取增加。药物与67Ga的联合使用对克隆形成能力产生相加效应。在通过纤维蛋白凝块技术培养的U937球体中,我们发现Ara-C预孵育后S期也有积累,转铁蛋白受体表达增加。与单细胞一样,67Ga摄取增加,但对克隆形成能力无协同作用。总之,药物预处理可诱导转铁蛋白受体表达增加和67Ga摄取增加。对克隆形成能力的抑制是相加的而非协同的。